Latest Phosphoinositide 3-kinase Stories
LONDON, Oct. 14, 2014 /PRNewswire/ -- REPORT HIGHLIGHTSThe global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012.
- Infinity to Receive $275 Million Upfront Payment and $530 Million in Potential Milestones - CAMBRIDGE, Mass. and NORTH CHICAGO, Ill., Sept.
According to a new report from BCC Research, the global market for signal transduction therapies/inhibitors (JAK and PI3K) is expected to grow to $2.2 billion by 2018, with a five-year compound
QUÉBEC CITY, April 9, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
QUÉBEC CITY, April 1, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
In the study by Toulany et al., it was demonstrated for the first time that long term treatment with inhibitors of PI3K (as it is performed clinically) results in a reactivation of the major survival component Akt through a so far unknown regulatory loop via ERK1/2.
Researchers from UCLA's Jonsson Comprehensive Cancer Center led an international team of scientists in conducting two studies that provide critical insights into two important ways that tumors resist BRAF inhibitors.
Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells.
Drivers of M&A in 2013-2016: Phosphoinositide 3-Kinases (PI3Ks) and Bruton’s Tyrosin Kinase (BTK) Inhibitors is the market research report available at ReportsnReports.com store.
A person’s hair color and skin tone is determined by their skin pigment. This pigment is influenced by the melanocortin-1 (MC1R) gene receptor. For the world’s redheads – one to two percent of the population – their coloration is accounted for by a mutation in MC1R.